Skip to main content
SpringerLink
Log in

Useful role for bisphosphonates in cancer-related bone disease

  • New Drugs and Therapeutics
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Compston JE. The therapeutic use of bisphosphonates. BMJ 1994; 309: 711–5

    Article  PubMed  CAS  Google Scholar 

  2. Hall TG, Burns Schaiff RA. Update on the medical treatment of hypercalcemia of malignancy. Clin Pharm 1993; 12: 117–25

    PubMed  CAS  Google Scholar 

  3. Coleman RE, Purohit OP. Osteoclast inhibition for the treatment of bone metastases. Can Treat Rev 1993; 19: 79–103

    Article  CAS  Google Scholar 

  4. Wimalawansa SJ. Hypercalcaemia of malignancy: etiology, pathogenesis and management. Rev Endocr Rel Cancer 1993; 45: 5–24

    Google Scholar 

  5. Patel S, Lyons AR, Hosking DJ. Drugs used in the treatment of metabolic bone disease: clinical pharmacology and therapeutic use. Drugs 1993; 46: 594–617

    Article  PubMed  CAS  Google Scholar 

  6. Bisphosphonates becoming increasingly important in Paget’s disease. Drug Ther Perspect 1994 May 2; 3(8): 7–8

    Google Scholar 

  7. Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42: 919–44

    Article  PubMed  CAS  Google Scholar 

  8. Plosker GL, Goa KL. Clodronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1994; 47: 945–82

    Article  PubMed  CAS  Google Scholar 

  9. Fitton A, McTavish D. Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991; 41: 289–318

    Article  PubMed  CAS  Google Scholar 

  10. Todd PA, Fitton A. Gallium nitrate: a review of its pharmacological properties and therapeutic potential in cancer-related hypercalcaemia. Drugs 1991; 42: 261–73

    Article  PubMed  CAS  Google Scholar 

  11. Physicians GenRx. New York: Data Pharmaceutica Inc, 1994

  12. British National Formulary No. 28. London: The Pharmaceutical Press, 1994; 299–300

  13. Dunn CJ, Fitton A, Sorkin EM. Etidronic acid: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging 1994; 5: 446–74

    Article  PubMed  CAS  Google Scholar 

  14. Ralston SH, Gallacher SJ, Patel U, et al. Comparison with three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet 1989; ii: 1180–2

    Article  Google Scholar 

  15. Gucalp R, Ritch P, Wiernik PH, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992; 10: 132–42

    Google Scholar 

  16. Rizzoli R, Buchs B, Bonjour J-P. Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate. Int J Cancer 1992; 50: 706–12

    Article  PubMed  CAS  Google Scholar 

  17. Ralston SH, Gardner MD, Dryburg FJ, et al. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet 1985; ii: 907–10

    Article  Google Scholar 

  18. Warrell Jr JRP, Murphy WK, Schulman P. A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia J Clin Oncol 1991; 9: 1467–75

    PubMed  Google Scholar 

  19. Thiébaud D, Jacquet AF, Burckhardt P. Fast and effective treatment of malignant hypercalcaemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate. Arch Intern Med 1990; 150: 2125–8

    Article  PubMed  Google Scholar 

  20. Averbuch SD. New bisphosphonates in the treatment of bone metastases. Cancer 72 (11 Suppl.): 3443–52

  21. Paterson AHG, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59–65

    PubMed  CAS  Google Scholar 

  22. Lahtinen R, Laakso M, Palva I, et al. Randomised, placebo controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992; 340: 1049–52

    Article  PubMed  CAS  Google Scholar 

  23. Kylmälä T, Tammela T, Risteli L, et al. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. Eur J Can 1993; 29A: 821–5

    Article  Google Scholar 

  24. Purohit OP, Anthony C, Radstone CR, et al. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1994; 70: 554–8

    Article  PubMed  CAS  Google Scholar 

  25. Glover D, Lipton A, Keller A, et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. Cancer 1994; 74: 2929–55

    Article  Google Scholar 

  26. van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 491–8

    PubMed  Google Scholar 

  27. Adamson BB, Gallacher SJ, Byars J. Mineralisation defects with pamidronate therapy for Paget’s disease. Lancet 1993; 342: 1459–60

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Useful role for bisphosphonates in cancer-related bone disease. Drugs Ther. Perspect 5, 1–5 (1995). https://doi.org/10.2165/00042310-199505040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199505040-00001

Keywords

Search

Navigation